Skip to main content
NVDA-2.84%AAPL-1.05%MSFT-0.61%GOOGL-12.64%AMZN-6.60%TSM-1.75%SPCX-0.92%AVGO-1.94%TSLA-2.27%META-1.49%LLY+6.57%BRK-B+0.30%SKHY-1.58%MU-5.12%WMT+2.09%AMD-2.08%JPM+1.26%V+2.48%XOM+0.70%JNJ+1.53%ASMLa-5.32%MA+4.16%ABBV+1.74%INTC-3.62%1398.HK+1.54%CVX+0.99%0700.HK+1.59%COST+1.36%CSCO-1.54%ORCL-3.45%KO+1.19%PG+1.47%UNH+0.94%BAC+0.57%0857.HK+5.66%AP2d-5.78%3988.HK+0.16%AMAT+1.36%HD+3.60%PM+2.89%GE+3.96%LRCX+0.22%0939.HK+1.28%1288.HK+1.31%1816.HK-2.24%NVS+3.22%DELL-3.74%0005.HK+0.15%MS-0.07%CAT-9.25%NZDCHF-1.37%GBPNZD+1.35%NZDCAD-1.28%AUDNZD+0.93%NZDUSD-0.93%EURNZD+0.90%CHFJPY+0.73%NZDJPY-0.68%GBPJPY+0.65%CADJPY+0.61%USDTRY+0.50%USDNOK-0.49%EURCHF-0.49%GBPZAR+0.47%USDCHF-0.45%AUDCHF-0.43%EURGBP-0.42%GBPTRY+0.41%GBPUSD+0.41%GBPAUD+0.40%AUDNOK-0.39%EURCAD-0.36%USDCAD-0.35%AUDCAD-0.35%EURNOK-0.33%USDSEK-0.32%GBPHKD+0.32%PLNJPY-0.30%GBPMXN-0.28%USDTHB-0.27%EURZAR+0.27%AUDJPY+0.25%USDCNH-0.25%USDJPY+0.24%EURJPY+0.24%USDSGD-0.21%NOKJPY+0.20%NZDMXN+0.19%EURPLN+0.18%USDDKK-0.17%GBPSGD+0.16%USDILS+0.16%EURSEK-0.16%EURHKD+0.16%CHFSGD+0.15%CHFNOK-0.13%USDZAR+0.10%CADCHF-0.10%AUDSGD-0.10%SGDJPY-0.08%EURCNH+0.07%AUDDKK-0.07%EURCZK-0.07%USDMXN-0.06%GBPCHF-0.05%NZDSGD+0.05%GBPCAD+0.04%EURSGD-0.04%USDHKD+0.04%USDCOP-0.04%CHFSEK+0.03%EURAUD-0.03%EURUSD-0.02%USDPLN+0.01%AUDUSD+0.01%EURDKK-0.01%GAGUSD-3.15%XAGUSD-3.15%XPTUSD-2.95%UKOIL+1.65%USOIL+1.26%HG1-1.11%XAUUSD-1.08%GAUUSD-1.08%SUGAR-0.82%XNGUSD+0.66%W1+0.46%C1-0.36%BTCUSD-0.03%ETHUSD+27.93%USDTUSD+0.08%XRPUSD+21.43%SOLUSD+22.08%TRXUSDT-5.36%ZECUSDT+4.06%DOGEUSD+24.76%XMRUSDT-1.47%LINKUSD+35.00%BCHUSDT+4.73%XLMUSD+2.51%UNIUSD+6.16%LTCUSD+21.89%SUIUSD+0.97%HBARUSDT+4.62%TONUSD+47.88%TAOUSDT+0.38%AAVEUSD+5.73%DOTUSDT+3.89%ICPUSDT+3.21%ONDOUSDT+3.28%WLDUSDT+4.43%ARBUSDT+6.23%JUPUSDT+2.56%ATOMUSDT+1.73%INJUSDT-1.18%STXUSDT+1.87%TIAUSDT-3.99%FETUSDT+1.43%PYTHUSDT-2.24%SEIUSDT+1.21%IMXUSDT+7.10%GRTUSDT-1.35%OPUSDT+3.38%WIFUSDT+5.12%POLUSDT+4.90%IOTAUSDT+3.49%AXSUSDT+0.78%EOSUSDT+2.27%FARTCOINUSDT+1.33%DYDXUSDT-0.50%GALAUSDT+3.01%ORDIUSDT+1.61%RONINUSDT+2.63%NOTUSDT+2.17%NVDA-2.84%AAPL-1.05%MSFT-0.61%GOOGL-12.64%AMZN-6.60%TSM-1.75%SPCX-0.92%AVGO-1.94%TSLA-2.27%META-1.49%LLY+6.57%BRK-B+0.30%SKHY-1.58%MU-5.12%WMT+2.09%AMD-2.08%JPM+1.26%V+2.48%XOM+0.70%JNJ+1.53%ASMLa-5.32%MA+4.16%ABBV+1.74%INTC-3.62%1398.HK+1.54%CVX+0.99%0700.HK+1.59%COST+1.36%CSCO-1.54%ORCL-3.45%KO+1.19%PG+1.47%UNH+0.94%BAC+0.57%0857.HK+5.66%AP2d-5.78%3988.HK+0.16%AMAT+1.36%HD+3.60%PM+2.89%GE+3.96%LRCX+0.22%0939.HK+1.28%1288.HK+1.31%1816.HK-2.24%NVS+3.22%DELL-3.74%0005.HK+0.15%MS-0.07%CAT-9.25%NZDCHF-1.37%GBPNZD+1.35%NZDCAD-1.28%AUDNZD+0.93%NZDUSD-0.93%EURNZD+0.90%CHFJPY+0.73%NZDJPY-0.68%GBPJPY+0.65%CADJPY+0.61%USDTRY+0.50%USDNOK-0.49%EURCHF-0.49%GBPZAR+0.47%USDCHF-0.45%AUDCHF-0.43%EURGBP-0.42%GBPTRY+0.41%GBPUSD+0.41%GBPAUD+0.40%AUDNOK-0.39%EURCAD-0.36%USDCAD-0.35%AUDCAD-0.35%EURNOK-0.33%USDSEK-0.32%GBPHKD+0.32%PLNJPY-0.30%GBPMXN-0.28%USDTHB-0.27%EURZAR+0.27%AUDJPY+0.25%USDCNH-0.25%USDJPY+0.24%EURJPY+0.24%USDSGD-0.21%NOKJPY+0.20%NZDMXN+0.19%EURPLN+0.18%USDDKK-0.17%GBPSGD+0.16%USDILS+0.16%EURSEK-0.16%EURHKD+0.16%CHFSGD+0.15%CHFNOK-0.13%USDZAR+0.10%CADCHF-0.10%AUDSGD-0.10%SGDJPY-0.08%EURCNH+0.07%AUDDKK-0.07%EURCZK-0.07%USDMXN-0.06%GBPCHF-0.05%NZDSGD+0.05%GBPCAD+0.04%EURSGD-0.04%USDHKD+0.04%USDCOP-0.04%CHFSEK+0.03%EURAUD-0.03%EURUSD-0.02%USDPLN+0.01%AUDUSD+0.01%EURDKK-0.01%GAGUSD-3.15%XAGUSD-3.15%XPTUSD-2.95%UKOIL+1.65%USOIL+1.26%HG1-1.11%XAUUSD-1.08%GAUUSD-1.08%SUGAR-0.82%XNGUSD+0.66%W1+0.46%C1-0.36%BTCUSD-0.03%ETHUSD+27.93%USDTUSD+0.08%XRPUSD+21.43%SOLUSD+22.08%TRXUSDT-5.36%ZECUSDT+4.06%DOGEUSD+24.76%XMRUSDT-1.47%LINKUSD+35.00%BCHUSDT+4.73%XLMUSD+2.51%UNIUSD+6.16%LTCUSD+21.89%SUIUSD+0.97%HBARUSDT+4.62%TONUSD+47.88%TAOUSDT+0.38%AAVEUSD+5.73%DOTUSDT+3.89%ICPUSDT+3.21%ONDOUSDT+3.28%WLDUSDT+4.43%ARBUSDT+6.23%JUPUSDT+2.56%ATOMUSDT+1.73%INJUSDT-1.18%STXUSDT+1.87%TIAUSDT-3.99%FETUSDT+1.43%PYTHUSDT-2.24%SEIUSDT+1.21%IMXUSDT+7.10%GRTUSDT-1.35%OPUSDT+3.38%WIFUSDT+5.12%POLUSDT+4.90%IOTAUSDT+3.49%AXSUSDT+0.78%EOSUSDT+2.27%FARTCOINUSDT+1.33%DYDXUSDT-0.50%GALAUSDT+3.01%ORDIUSDT+1.61%RONINUSDT+2.63%NOTUSDT+2.17%
RI

Recordati Industria Chimica e Farmaceutica S.p.A. (RECm)

Euronext Milan • Healthcare

€53.02
+€0.02 (+0.0%)
Market open

October 30, 2026 at 11:01 UTC

Open€52.95
Previous Close€53
Day Range€52.95 - €53.05
Avg. Volume (3M)393.1K
Market Cap€10.8B
P/E Ratio21.8
52 Week Range
€43.76€54.45

Interactive Chart

11:01:12 UTC

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned€697.3M100%
Gross Profitminus cost of goods€497.9M71%
Operating Incomeminus R&D and overhead€203.6M29%
Net Incomeminus taxes and the rest€116.6M17%

In plain terms: out of every €100 in revenue, Recordati Industria Chimica e Farmaceutica S.p.A. keeps €17 as net profit.

Fundamentals & Financials

Revenue (TTM)
€2.7B
Net Income (TTM)
€497.1M
EPS (TTM)
€2.43
ROA (TTM)
9.26%
Current Ratio
1.26
Dividend Yield
1.37%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+48.6%Q1 2020€0.55
+17.8%Q2 2020€0.53
-12.8%Q3 2020€0.41

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2020
Miss -12.8%

Recordati Industria Chimica e Farmaceutica’s revenue rose 8.3% to about EUR 697 million in the second fiscal quarter of 2026, reported on July 28, with gross profit near EUR 498 million and gross margin around 71%. Operating income reached about EUR 204 million, leaving operating margin close to 29%, while net income increased 28.0% to about EUR 117 million from EUR 91.1 million a year ago. EPS came in at EUR 0.57, up 30.9% from EUR 0.44 a year earlier, and operating cash flow came to about EUR 217.1 million. The company also paid about EUR 143 million in dividends.

Next report — what to expect

Recordati Industria Chimica e Farmaceutica SpA (REC.MI) is due to report next earnings on unknown. Recent results showed trailing revenue up +8.3% year over year last quarter. On surprises, the company has beaten EPS in 1 of 8 most recent quarters, making consistency versus expectations a key item to watch.

View full earnings history

About Recordati Industria Chimica e Farmaceutica S.p.A.

Recordati Industria Chimica e Farmaceutica S.p.A. produces, commercializes, and distributes medicinal products and related healthcare goods worldwide, while also researching and developing them. Listed as REC.MI on MIL, the company operates in pharmaceuticals and recorded EUR 2.6 billion of revenue in FY2025.

Name
Recordati Industria Chimica e Farmaceutica S.p.A.
CEO
Robert Koremans
Website
www.recordati.com
Industry
Healthcare
Year Founded
1926
Employees
4,693

Today's Snapshot

AI-generated

RECm opened flat at 53.00, while its sector was firmer. RECm is trading within 2.8% of its 52-week high of 54.45. CVC-backed buyer bought more Recordati shares, increasing its ownership.

Trading Volume

Below 10d avg (366.0K)

3.9K

vs S&P 500 Today

Moderate Outperformance

+0.21%

Updated: October 30, 2026 at 09:39 UTC

RECm Headlines

CVC’s €10.7bn Recordati Bid Faces Revolt

September 13, 2026

2 min read
View All News

Technical Indicators

3 Buy3 Neutral2 Sell
RECm presents a cautiously positive setup with a moderate trend indicated by ADX and volume measures on-balance volume showing support, while momentum indicators are largely neutral. The price is hovering around short-term averages and remains above the 200-day, suggesting longer-term support even as the 10–20 period averages are marginally mixed. Volatility is low as reflected by ATR and pivots are close to price, underscoring a balanced near-term bias. Technical takeaway: Buy.
All signals
  • EMA (5 indicators)$50.92 - $53.00
    Buy
  • RSI (14)50.96
    Neutral
  • Stochastic %K (14, 3, 3)20.63
    Neutral
  • MACD Level (12, 26)0.08
    Neutral

Peers & Related Assets

BIIBBiogen Inc.
$249.65+2.3%
ALNYAlnylam Pharmaceuticals, Inc.
$174-25.1%
JAZZJazz Pharmaceuticals plc
$207.83+1.4%
BMRNBioMarin Pharmaceutical Inc.
$57.49+2.7%
CORTCorcept Therapeutics Incorporated
$85.95-0.4%
4151.TKyowa Kirin Co., Ltd.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.